Case report highlights the severe bradycardia and muscle weakness due to triple M syndrome, indicating heightened vigilance for immune-related adverse events.
Key Points
The patient developed severe bradycardia and muscle weakness after pembrolizumab therapy.
Despite echocardiography showing normal results, the patient faced worsening symptoms and respiratory failure.
A comprehensive diagnostic approach is essential as autoantibody markers may be absent in conditions like myocarditis.
Monitoring for immune-related adverse events is crucial for improving clinical outcomes in patients undergoing cancer treatment.